Condition
Carcinoma, Adenoid Cystic
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (1)
P 2 (3)
Trial Status
Recruiting2
Unknown2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05733910Not ApplicableRecruitingPrimary
Simultaneous Integrated Boost in Carbon Ion Radiotherapy for Head and Neck Adenoid Cystic Carcinoma
NCT04974866Phase 2RecruitingPrimary
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma
NCT03291002Phase 1Unknown
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
NCT01065844Phase 2CompletedPrimary
Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck
NCT00180921Phase 2Unknown
Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck
Showing all 5 trials